Beroni Group Limited New R&D Centre in High-Tech Hub in Zhuhai, China

Sydney, Australia (ABN Newswire) - Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it has signed a contract to build a new Research & Development ("R&D") centre in the Zhuhai National High-Tech Industrial Development Zone in China. Beroni aspires to build a state-ofthe-art facility with new preclinical research labs, manufacturing process development labs, and a GMP pilot manufacturing plant.

The new R&D centre -- the first R&D site for Beroni -- will help the Company develop new drugs and medicines to cater for the vast needs of the Chinese market. To start with, the Company will occupy about 4,000 square metres (44,000 square feet) of office space for setting up the GMP plant and laboratories. Construction of the new R&D facilities is expected to be completed towards the end of the second quarter, and the entire R&D centre is expected to be ready in the second half of this year. Beroni intends to commit US$10 million to support the clinical trials in the new R&D facility. A new company, Beroni Pharmaceutical (Guangdong) Co., Ltd, has been established for this new venture with Beroni owning 80% of the entity's shares and a local investor owning the other 20% shares. The Company will bring professional staff, scientists, technicians, and support teams together into a state-of-the-art hub for innovation and development of the company's future products and services.

Beroni has a drug development pipeline focusing on oncology and immunotherapy. It is moving ahead with the Phase II clinical trial of the anti-cancer molecular drug, PENAO later this year and is scheduled to commence the clinical trials for a few cellular therapies including gamma delta T cell, DC vaccine, and protein modifier R8. It is also currently studying the use of single-domain antibodies for treatment of coronavirus diseases.

"Establishing a new R&D centre in Zhuhai will allow us to expand our R&D capabilities and accelerate our innovative pipeline," said CEO Jacky Zhang. "In the future, we plan to establish additional R&D centres around the world to advance the discovery and development of new innovative product candidates."

The Zhuhai National High-Tech Industrial Development Zone Valley, established in 1992, is one of the top biotech hubs in China and is home to hundreds of innovative biotechnology and biopharmaceutical companies. It covers an area of 139 square kilometres and boasts a convenient transportation network with the Beijing-Zhuhai Expressway, Western Guangdong Coastal Expressway and Guangzhou-Zhuhai Intercity MRT passing through the area. Ideally placed for business opportunities, the zone has the location advantage of being within the "One-Hour Economic Circle" of the Pearl River Delta.



About Beroni Group Limited:  

Beroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.



Source:
Beroni Group Limited



Contact:
Dragon Gate Investment Partners LLC
Tel: +1(646)-801-2803
Email: BNIGF@dgipl.com

News Provided by ABN Newswire via QuoteMedia

BTO:CA,BTG
The Conversation (0)
Omar ayales, gold bars.

Omar Ayales: Gold, Silver, Juniors Have Explosive Upside — Not Being in Trade is Top Risk

Speaking to the Investing News Network, Omar Ayales of Gold Charts R Us discussed the outlook for gold from a technical perspective, saying that he sees the metal's price potentially peaking in 2026.

Gold's past performance indicates that it could reach US$4,000 per ounce during this cycle. He sees US$2,600 as a bullish support level for gold, with deeper support existing in the US$2,200 to US$2,300 range.

However, Ayales said there's no guarantee that the yellow metal will fall that low at this point.

Keep reading...Show less
Business handshake.

Newmont to Sell Cripple Creek & Victor Mine Amid Firm-wide Restructuring

Newmont (TSX:NGT,NYSE:NEM) announced the sale of its Cripple Creek & Victor mine in Colorado, US, to SSR Mining (TSX:SSRM,NASDAQ:SSRM) for up to US$275 million, continuing its ongoing restructuring efforts.

Under the terms of the deal, Newmont will receive US$100 million in cash upon closing, with an additional US$175 million contingent on regulatory approvals and conditions related to the Carlton Tunnel.

Newmont has agreed to bear 90 percent of potential closure costs exceeding US$500 million under a future regulator-approved closure plan. The transaction is expected to close in the first quarter of 2025.

Keep reading...Show less
Black swan and many white swans on piles of gold coins.

Black Swans, White Swans and Trump’s Clash with the Fed

The Trump administration’s ability to reign in government spending, quash inflation and bolster the economy were the most prevalent topics during the popular economy panel at the New Orleans Investment Conference.

Moderated by Adrian Day, president Adrian Day Asset Management, this year’s discussion featured James Lavish, Jim Bianco, Dr. Mark Skousen, Brent Johnson and James Grant. The expert group began the discussion by debating the potential economic impact Donald Trump could have, highlighting contradictions in his policies.

Johnson, who is CEO of Santiago Capital, pointed out that Trump's anti-inflation stance conflicts with his push for a weak US dollar and tariffs, which Johnson likened to global rate hikes.

Keep reading...Show less
Gold bear and bull fighting over bars of gold.

Gold Price 2024 Year-End Review

Gold saw incredible price gains in 2024, rising from US$2,000 per ounce to close to US$2,800.

Various factors have lent support, including 75 basis points worth of interest rate cuts from the US Federal Reserve, geopolitical instability in Eastern Europe and the Middle East and uncertainty in global financial markets.

Of course, it wasn't all an upward climb for gold — following the US presidential election, Donald Trump emerged victorious, and the gold price experienced volatility as investors flocked to Bitcoin.

Keep reading...Show less
Marc Ducler, managing director of Astral Resources.

Astral Resources Eyes Gold Production at Mandilla Project in Western Australia

Australia-based gold explorer and developer Astral Resources (ASX:AAR) is riding the strong gold price wave as it ramps up exploration and moves toward a prefeasibility study — and ultimately production — at its flagship Mandilla project.

Managing Director Marc Ducler outlined the positive economics for Mandilla, which is in Western Australia. He said they have improved significantly since a scoping study for the project was released in September 2023.

“We were (projecting) a net present value of AU$440 million. And that's at AU$2,750 (for the gold price). You move it to the gold price today, and we have a project that has AU$1.2 billion in net present value and is capable of providing over AU$285 million worth of free cashflow every single year,” he explained.

Keep reading...Show less

Latest Press Releases

Related News

×